Login to Your Account



Acacia’s Series B Adds $24M For PONV Drug; NDA in 2014

By Nuala Moran
Staff Writer

Wednesday, September 4, 2013
LONDON – Acacia Pharma Ltd. raised £15 million (US$23.5 million) in a Series B funding, providing the means to complete Phase III development of its lead product, APD421, for the prevention of postoperative nausea and vomiting (PONV), and to file a new drug application around the middle of 2014.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription